Foley Hoag LLP represented Thermo Fisher Scientific (NYSE: TMO), a world leader in serving science, in acquiring Combinati Incorporated and its digital PCR (dPCR) technology. dPCR has quickly become the standard for nucleic acid quantification in oncology, cell and gene therapy development and other research applications because its absolute quantification enables higher accuracy and precision.
Thermo Fisher is the world leader in serving science, with annual revenue of approximately $35 billion. The company’s mission is to enable its customers to make the world healthier, cleaner and safer. Thermo Fisher’s global team of more than 90,000 colleagues delivers a combination of innovative technologies, purchasing convenience and pharmaceutical services through its industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.
Foley Hoag attorneys Joe Basile, Adrienne Ellman, Zohar Nevo, Sarah Moore
, Marcus Sands, Teresa Martland
, Jonathan Keselenko
, Areta Kupchyk
, Earl Mellott
, Chasse Osborn
and Jeffrey Lewis
represented Thermo Fisher in the transaction.